Condition
Follicular Lymphomas
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (1)
P 3 (2)
Trial Status
Completed3
Active Not Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07505849Phase 2Not Yet RecruitingPrimary
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
NCT00991211Phase 3Completed
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
NCT00877214Phase 3Active Not RecruitingPrimary
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
NCT02650999Phase 1Completed
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas
NCT01474681Phase 1Completed
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Showing all 5 trials